Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00324155 · ClinicalTrials.gov registry record · Phase 3
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 681
- Enrollment target
NCT00324155 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 681 participants.
The verdict
NCT00324155, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 681 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to examine the safety and effectiveness (how well the drug works) of two different treatments for patients with melanoma. One treatment is an investigational compound (a drug that is not currently approved by the United States Food and Drug Administration \[FDA\]), know as Ipilimumab (also known as MDX-010 or BMS-734016) together with an approved chemotherapy drug called Dacarbazine
Interventions
- DRUG Placebo
- DRUG Ipilimumab
- DRUG Dacarbazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 681 participants |
| Start Date | 2006-08 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00324155
The ClinicalTrials.gov registry entry for NCT00324155 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 681 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00324155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00324155 about?
NCT00324155 is a clinical study titled "Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma". The purpose of this clinical research study is to examine the safety and effectiveness (how well the drug works) of two different treatments for patients with melanoma. One treatment is an investigational compound (a drug that is not currently approved by the United States Food and Drug Administrati...
What is the current status of trial NCT00324155?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 681 participants. The study started on 2006-08. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00324155?
The interventions under investigation include: Placebo (DRUG), Ipilimumab (DRUG), Dacarbazine (DRUG).
Who is sponsoring clinical trial NCT00324155?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.